Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 6 Issue 10, October 2006

From The Editors

Top of page ⤴

Research Highlight

Top of page ⤴

In the News

Top of page ⤴

Research Highlight

Top of page ⤴

Trial Watch

Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Research Highlight

Top of page ⤴

Review Article

  • The FDA recently approved a human papillomavirus preventive vaccine for cervical cancer, the second largest cause of cancer deaths in women. How will the introduction of this vaccine affect cervical cancer incidence and what are the outstanding issues?

    • Richard Roden
    • T.-C. Wu
    Review Article
  • Cysteine cathepsins are proteolytic enzymes whose expression is increased in both tumour and tumour-associated cells. What is known about the extracellular and intracellular functions of these enzymes in cancer?

    • Mona Mostafa Mohamed
    • Bonnie F. Sloane
    Review Article
  • Ubiquitin and ubiquitin-like proteins (Ubls) participate in many cellular processes, such as apoptosis and DNA repair. How can the deregulation of ubiquitin and Ubls lead to cancer formation, and how might ubiquitin and Ubl pathways be targeted by anticancer therapeutics?

    • Daniela Hoeller
    • Christina-Maria Hecker
    • Ivan Dikic
    Review Article
  • Nuclear DNA topoisomerase I (TOP1) is an essential human enzyme, and is the only known target of the camptothecin and its derivatives. The mechanisms and molecular determinants of the tumour response to TOP1 inhibitors are reviewed in the context of developing camptothecin and non-camptothecin derivatives that further increase anti-tumour activity but also reduce side effects.

    • Yves Pommier
    Review Article
  • Most cancer patients who are treated with epidermal growth factor receptor inhibitors (EGFRIs) develop dermatological toxicities owing to the important function of the EGFR signalling pathway in the skin. How do EGFRIs affect the skin and what treatments are needed to avoid these undesirable side effects?

    • Mario E. Lacouture
    Review Article
Top of page ⤴

Timeline

  • The US National Cancer Institute (NCI) 60 human tumour cell line anticancer drug screen (NCI60) was developed nearly 20 years ago, and is a valuable source of information about anticancer drug leads and mechanisms of growth inhibition.

    • Robert H. Shoemaker
    Timeline
Top of page ⤴

Correspondence

Top of page ⤴

Search

Quick links